Sun Pharma launches Palbociclib, therapy for advanced breast cancer

Sun Pharma today announced that one of its wholly-owned subsidiaries has launched a novel anti-cancer drug, Palbociclib, in India, for patients who have advanced breast cancer. The company will make the drug available under the brand name, Palentom, (Palbociclib) 75 mg, 100 mg, 125 mg, a statement from the company said.

Palbociclib is approved by the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA) and the Central Drugs Standard Control Organization (CDSCO), in combination with hormonal therapies for patients with hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer, the statement added.

Kirti Ganorkar, CEO, India Business, Sun Pharma, said in the statement, “We are introducing Palbociclib at an affordable price which will help improve patient access. Paleno will address the treatment need of several advanced breast cancer patients in India. For the first time, we are introducing a unique patient assistance programme that will improve patient compliance and accessibility.”